吸入性肺炎厌氧菌覆盖的获益与风险:回顾性队列研究
该多中心回顾性队列研究纳入安大略省18家医院2015至2022年因社区获得性吸入性肺炎住院并接受指南一致性一线肠外抗生素治疗的患者,比较有限厌氧菌覆盖(LAC)与扩展厌氧菌覆盖(EAC)的院内死亡率和艰难梭菌结肠炎风险。结果显示EAC组院内死亡率无额外获益,但艰难梭菌结肠炎风险显著增加。
要点
- 扩展厌氧菌覆盖未降低吸入性肺炎院内死亡率。
- 扩展厌氧菌覆盖增加艰难梭菌结肠炎风险。
- 吸入性肺炎可能无需常规扩展厌氧菌覆盖。
核心结论
- 扩展厌氧菌覆盖在吸入性肺炎中可能不必要,因为其与无额外死亡率获益相关,仅增加艰难梭菌结肠炎风险。
研究设计与样本
- 多中心回顾性队列研究,纳入加拿大安大略省18家医院2015年1月1日至2022年1月1日因社区获得性吸入性肺炎住院并接受指南一致性一线肠外抗生素治疗的患者。
- LAC组接受头孢曲松、头孢噻肟或左氧氟沙星;EAC组接受阿莫西林-克拉维酸、莫西沙星或头孢曲松/头孢噻肟/左氧氟沙星联合克林霉素或甲硝唑。
- 采用倾向评分重叠权重平衡基线预后因素。
主要发现
- LAC组2683例,EAC组1316例;院内死亡分别为814例(30.3%)和422例(32.1%)。
- 艰难梭菌结肠炎在LAC组≤5例(≤0.2%),EAC组11至15例(0.8%-1.1%)。
- 倾向评分重叠权重后,EAC减LAC的调整风险差:院内死亡率1.6%(95%CI,-1.7%至4.9%),艰难梭菌结肠炎1.0%(95%CI,0.3%至1.7%)。
临床怎么用
- 临床治疗社区获得性吸入性肺炎时,可考虑不常规扩展厌氧菌覆盖,以降低艰难梭菌结肠炎风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibiotics with extended anaerobic coverage are used commonly to treat aspiration pneumonia, which is not recommended by current guidelines. RESEARCH QUESTION: In patients admitted to hospital for community-acquired aspiration pneumonia, does a difference exist between antibiotic therapy with limited anaerobic coverage (LAC) vs antibiotic therapy with extended anaerobic coverage (EAC) in terms of in-hospital mortality and risk of Clostridioides difficile colitis? STUDY DESIGN AND METHODS: We conducted a multicenter retrospective cohort study across 18 hospitals in Ontario, Canada, from January 1, 2015, to January 1, 2022. Patients were included if the physician diagnosed aspiration pneumonia and prescribed guideline-concordant first-line community-acquired pneumonia parenteral antibiotic therapy to the patient within 48 h of admission. Patients then were categorized into the LAC group if they received ceftriaxone, cefotaxime, or levofloxacin. Patients were categorized into the EAC group if they received amoxicillin-clavulanate, moxifloxacin, or any of ceftriaxone, cefotaxime, or levofloxacin in combination with clindamycin or metronidazole. The primary outcome was all-cause in-hospital mortality. Secondary outcomes included incident C difficile colitis occurring after admission. Overlap weighting of propensity scores was used to balance baseline prognostic factors. RESULTS: The LAC and EAC groups included 2,683 and 1,316 patients, respectively. In hospital, 814 patients (30.3%) and 422 patients (32.1%) in the LAC and EAC groups died, respectively. C difficile colitis occurred in five or fewer patients (≤ 0.2%) and 11 to 15 patients (0.8%-1.1%) in the LAC and EAC groups, respectively. After overlap weighting of propensity scores, the adjusted risk difference of EAC minus LAC was 1.6% (95% CI, -1.7% to 4.9%) for in-hospital mortality and 1.0% (95% CI, 0.3%-1.7%) for C difficile colitis. INTERPRETATION: We found that extended anaerobic coverage likely is unnecessary in aspiration pneumonia because it was associated with no additional mortality benefit, only an increased risk of C difficile colitis.
引用
- Bai, Srivastava, Digby, et al. Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms: A Retrospective Cohort Study. Chest. 2024. PMID: 38387648. doi:10.1016/j.chest.2024.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。